STOCKS TELEGRAPH

Author: Shimrez Hyder

  • CooTek Inc. (CTK) Stock on the Rise Following Promising Financial Reports for Q2 2021

    CooTek Inc. (CTK) Stock on the Rise Following Promising Financial Reports for Q2 2021

    CooTek Inc. (CTK) stock prices were up 5.59% some time after market trading commenced on September 8th, 2021. This brought the price per share up to USD$1.51 early on in the trading day.

    CTK Stock’s Return to Profitability

    The company reported a return to profitability as it maintained positive quarter-over-quarter revenue growth over the second quarter of 2021. CTK stock is keen to continue its commitment to its content-focused strategy. It facilitates this by continuously enhancing its product portfolio, while optimizing product features. The company is bolstered by the success of the implementation of its business plan, driven by online literature and proprietary mobile game products.

    Strength of Revenues

    Consolidated by enriching and high quality content incubation, Fengdu Novel has been facilitating the expansion of its exclusive content distribution and IP business. The revenues from the IP business reported a 194% growth as compared to the prior quarter. Furthermore, the company’s mobile games portfolio has seen a consolidation in both domestic and international markets. The company has striven to capitalize on the momentum generated by its top-ranking casual game, Catwalk Beauty. This is in the interest of forming a competitive product pipeline. The second half of 2021 is expected to see the company sell more than 15 games in the domestic market and more than 20 in overseas markets.

    CTK Stock’s Continued Development

    CTK stock is continuing to allocate resources towards the upgrading of its business model. This has entailed an optimizing of the balance between marketing and monetization strategies. This, in turn, has resulted in the achievement of group level profitability in the second quarter of fiscal 2021. The company has plans to further expand the scale of its product portfolio. This move is expected to improve user experience and user stickiness, while enhancing monetary capabilities. Net revenues for the second quarter of 2021 came in at USD$83.2 million. This represented a 34% decrease from the prior year quarter, driven by a decrease in mobile advertising revenues.

    Future Outlook for CTK Stock

    The company reported a promising quarter, evidenced by the strength of its financial reports for Q2 2021. CTK stock is poised to capitalize on the opportunities afforded to it as a result of  the momentum generated over the quarter. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.

  • Hoth Therapeutics Inc. (HOTH) Stock Faces Minor Correction of Surge After Positive Phase 1b Results for BioLexa

    Hoth Therapeutics Inc. (HOTH) Stock Faces Minor Correction of Surge After Positive Phase 1b Results for BioLexa

    Hoth Therapeutics Inc. (HOTH) stock prices were down by 2.99% shortly after market trading commenced on September 8th, 2021. This brought the price per share down to USD$1.30 early on in the trading day.

    Positive Phase 1b Results

    September 8th, 2021 saw HOTH stock announce the completion of its safety results for Cohort 1 of its first in a human clinical trial. The trial is in regard to the company’s BioLexa platform. BioLexa is designed to treat atopic dermatitis, which is also known as eczema. The first cohort of the phase 1b trial enrolled healthy patients. These patients were administered topical BioLexa twice a day for 14 days as a part of the randomized, placebo-controlled trial.

    HOTH Stock’s Trial Details

    The primary endpoint of the two-part study is designed to evaluate the safety profile of the treatment. It will also characterize the pharmacokinetics of topical BioLexa Lotion. Preliminary efficacy data will be collected as a part of the cohort 2 phase with patients. No serious adverse events or drug-related treatment-emergent adverse events were observed during the execution of cohort 1. HOTH stock’s BioLexa trial is continuing on schedule, with the initiation of Cohort 2 expected soon for patients with mild to moderate atopic dermatitis.

    About BioLexa

    BioLexa has been patented as the company’s proprietary antimicrobial topical formulation is being developed for the treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities that are comprised of bacteria adhering to a surface (both biological and abiotic surfaces). The bacteria also adhere to other bacteria, as well as with a protective extracellular matrix. Maturation of bacterial biofilms have been shown to cause chronic and recurrent infections that are difficult to treat due to the barrier effect of the biofilm that facilitates antibiotic resistance and the avoidance of immune system mechanisms.

    Scope of HOTH Stock’s Study

    The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation. This ensures that bacteria are in a more susceptible state to antimicrobial therapies. The novel mechanisms of action at play have the potential to address and treat the broad clinical manifestations arising from Staphylococcal biofilm formation.

    Future Outlook for HOTH Stock

    HOTH stock reported a promising quarter, consolidated by the success of its positive Phase 1b results for its BioLexa platform. The company is keen to capitalize on the opportunities afforded to it as it continues to leverage the resources at its disposal. Current and potential investors are hopeful that this will facilitate significant and sustained increases in shareholder value.

  • WiMi Hologram Cloud Inc. (WIMI) Stock on the Rise Following Launch of WiMi HoloAR Lens

    WiMi Hologram Cloud Inc. (WIMI) Stock on the Rise Following Launch of WiMi HoloAR Lens

    WiMi Hologram Cloud Inc. (WIMI) stock prices opened and closed at USD$4.62 on September 7th, 2021. Premarket fluctuations saw the stock rise by 5.19%, bringing it up to USD$4.86.

    WiMi Stock Launches HoloAR Lens

    September 7th 2021 saw WIMI stock announce the release of its new augmented reality (AR) head-mounted display (HMD) product for the consumer market. The new WiMi HoloAR lens will serve to further strengthen the software and hardware research and development of the underlying holographic technology. The holographic AR application technology provider is also facilitating the expansion of its user experience of holographic AR technology in Metaverse.

    Scope of WiMi HoloAR Lens

    The company’s new AR-HMD product WiMi HoloAR Lens is the first split glasses that is also compatible with the dual-camera and function of 6 degree of freedom spatial positioning solution in the world. The technology allows for the full use of spatial interaction, proving suitable for multiple scenes such as spatial interaction and spatial positioning. The holographic AR technology has been upgraded for the new applications, thereby benefitting multi-application development and promotion of user experience of the Metaverse.

    Scope of WIMI Stock’s Product

    Parameters of WIMI stock’s new technology are better than products in the same category, with the WiMi HoloAR Lens proving to be more user-friendly and easy-to-wear. The AR display device can be extended to connect to personal computers, drones, Android and iOS smartphones. This facilitates the portability and mobility of the smart display device in multiple scenarios. The device offers a 63 degree viewing angle, as compared to the industry standard of 30 to 55 degrees.

    Product Parameters

    The product boasts a 600-inch long giant screen display, 1920*1080p high definition picture, a contrast ratio of 50000/1, and 80 million full colors. In conjunction with the high brightness screen of 1800nit and the stellar refresh rate of 90 Hz, WIMI stock’s HoloAR Lens allows for a clearer and more realistic display effect. the machine mitigates the physical strain on users as a result of its weighing a meagre total of 78 grams.

    Future Outlook for WIMI Stock

    WIMI stock reported a promising quarter, cemented by the company’s launch of its new WiMi HoloAR Lens technology. Management is keen to leverage the resources at their disposal to facilitate the spearheading of the proliferation of its newest product. Current and potential investors are hopeful that management will be able to usher in consistent increases in shareholder value over the long term.

  • Waterdrop Inc. (WDH) Stock Surges Following Promising Financial Reports for Q2 2021

    Waterdrop Inc. (WDH) Stock Surges Following Promising Financial Reports for Q2 2021

    Waterdrop Inc. (WDH) share prices were up by 5.67% as of the market closing on September 7th, 2021. This brought the price per share to reach at $3.73 in the trading day. Subsequent pre-market fluctuations saw the stock surge by 16.89%, bringing the price above $4.

    WDH Stock’s Recent Developments

    WDH stock’s listing on the New York Stock Exchange in Q2 2021 was a substantial milestone in the company’s history since its inception. Capital markets have recent undergone an increase in volatility, while several industries in China have entered a period of transformation. These factors have served to negatively impact investor sentiment. The company’s well-established business infrastructure. Organizational capabilities and competitive advantages will serve to facilitate efficient adapting to new trends and challenges as they come up. WDH stock’s Board approved a share repurchase program, the launch of which consolidates confidence in long-term sustainable development and consistent commitment to generating shareholder value.

    Expansion of Consumer Base

    The company is allocating resources towards serving a broader range of users with better customer experience, as well as developing products and services that are personalized for different demographics. WDH stock is also contributing to new innovating on the supply side. The second quarter of fiscal 2021 saw the company report encouraging progress in expanding its existing product portfolio. This includes, but is not limited to, cancer insurance, outpatient medical insurance, and critical illness insurance for substandard groups. the company has also been facilitating channel development as it seeks out promising investment opportunities to drive external traffic.

    Staying Up to Date

    WDH stock is aiming to improve its efficiency in external traffic channels, facilitated by the increase in its use of technological applications and automatic service tools. The company is confident that recent regulatory initiatives will serve to benefit the long-term development of the industry. Management will continue to allocate resources towards staying up to date and fully compliant with regulatory requirements. The company is keen to take the lead in upgrading and optimizing its business model for online insurance.

    Future Outlook for WDH Stock

    The company had a promising quarter, as evidenced by the strength of its financial reports for the second quarter of fiscal 2021. WDH stock is poised to capitalize on the momentum it has generated over the end of the first half of fiscal 2021. Investors are hopeful that management will be able to usher inconsistent increases in shareholder value over the long term.

  • Amyris Inc. (AMRS) Stock Exhibits Minor Volatility Following Acquisition of Beauty Labs International

    Amyris Inc. (AMRS) Stock Exhibits Minor Volatility Following Acquisition of Beauty Labs International

    Amyris Inc. (AMRS) stock prices were down by 3.84% as of the market closing on September 7th 2021. This brought the price per share down to USD$13.29 at the end of the trading day. Subsequent premarket fluctuations saw the stock increase by 3.01%, bringing it up to USD$13.69.

    Acquisition of Beauty Labs International

    September 7th 2021 saw the company announce the closing of its acquisition of Beauty Labs International on August 31st 2021. AMRS stock’s collaboration with the leading AI technology firm will accelerate the company’s growth and market leadership in clean beauty. This will be facilitated by the addition of digital innovation, machine learning, and data science to improve the customer experience of its network of consumer brands. These brands will leverage the partner’s leading AI technology to create engaging and personalized connected consumer experiences, thereby further accelerating the growth of Amyris’ ecommerce revenue.

    Facilitating Further Growth

    The company has initiated the combination of Beauty Labs technology into its direct-to-consumer websites. Thus far, positive results have been reported for the Rose Inc. direct-to-consumer channel of a higher conversion to purchase using the color matching technology. In addition to the acquisition of MG Empower in the previous month, AMRS stock is leveraging its strategy of deepening the beauty consumer relationship. This will result in the delivery of the best possible digital retail beauty experience.

    AMRS Stock Racing Towards Commercialization

    These technologies complement AMRS stock’s unique portfolio connection from the creation of differentiated sustainable ingredients by its Lab-to-Market science and technology, to the formulation into better consumer products. The company’s progress towards the manufacturing at scale and commercializing of ingredients is outpacing its peer group in synthetic biology.

    AMRS Stock’s Diversification

    Squalene, Hemisqualene, Biosilica, and CBG are AMRS stock’s ingredients that are naturally produced  from clean fermentation. These ingredients differentiate consumer-oriented products and facilitate substantial growth in the company’s revenue. The success of the company’s vertically integrated business model is demonstrated by the bridge between ingredients, clean beauty products, and ecommerce technologies.

    Future Outlook for AMRS Stock

    The company reported a promising quarter, consolidated by its most recent acquisition of Beauty Labs International. AMRS stock is poised to capitalize on the opportunities afforded to it as a result of this expansive partnership. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.

  • RenovoRx Inc. (RNXT) Stock Surges Following U.S. FDA Approval for RenovoCath Delivery System

    RenovoRx Inc. (RNXT) Stock Surges Following U.S. FDA Approval for RenovoCath Delivery System

    RenovoRx Inc. (RNXT) stock prices surged by 19.14% some time after market trading commenced on September 7th 2021. This brought the price per share up to USD$9.43 early on in the trading day.

    RenovoCath Delivery System Approval

    September 7th 2021 saw RNXT stock announce having received a new 510(k) clearance for its proprietary RenovoCath Delivery System by the United States Food and Drug Administration. The RenovoCath Delivery System is the device component of the company’s initial product, RenovoGem. The drug/device combination used in the company’s Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform is a dual-balloon infusion catheter. It facilitates the delivery of chemotherapy directly to tumors via arteries. The new design allows for a more targeted delivery of therapy, resulting in an effective treatment with minimal side effects.

    Scope of RenovoTAMP Therapy Platform

    The novel RenovoTAMP therapy platform isolated wherever the disease is located, thereby enabling the delivery of the optimal dose of targeted chemotherapy to the tumor location. The recent clearance from the U.S FDA will serve to further improve the technology’s targeted delivery, with a focus on improving patient survival while mitigating side effects for oncology patients. The company’s novel therapy platform is designed to deliver established therapies for the localized treatment of solid cancer tumors. It has the potential to allow physicians to isolate the anatomy and micro=perfuse targeted tissue with small molecule chemotherapy.

    RNXT Stock’s TIGeR-PaC Clinical Trial

    August 15th 2021 saw the company’s Phase 3 TIGeR-PaC clinical trial reach 44% patient enrollment. The randomized study makes use of the RenovoTAMP platform to evaluate RenovoGem and is designed to treat pancreatic cancer. The study is currently in the process of enrolling locally advanced, pancreatic cancer patients. Clinical studies thus far have shown chemotherapy delivered with the RenovoTAMP platform was linked to more than half the patients living for more than 2 years. Standard-of-care has typically resulted in pancreatic cancer patients surviving 12 to 15 months from the date of their diagnosis. The study has 30 active clinical sites, and is expected to involved roughly 200 participants in the U.S and Europe.

    Future Outlook for RNXT Stock

    The company reported a strong quarter, most recently consolidated by the U.S FDA’s approval of the company’s RenovoCath Delivery System. RNXT stock is poised to capitalize on the opportunities afforded to it as it pushes for the accelerated commercialization and proliferation of its flagship technology. Current and potential investors are hopeful that management will be able to facilitate significant and sustained increases in shareholder value over the long term.

  • Eyegate Pharmaceuticals Inc. (EYEG) Stock Exhibits Minor Volatility Following Success of Financial Reports for Q2 2021

    Eyegate Pharmaceuticals Inc. (EYEG) Stock Exhibits Minor Volatility Following Success of Financial Reports for Q2 2021

    Eyegate Pharmaceuticals Inc. (EYEG) stock prices surged 0.27% to USD$3.75 shortly after market trading commenced on September 7th 2021.

    EYEG Stock’s R&D Expenses

    Research and development expenses came out to USD$1.44 million for the second quarter of fiscal 2021. This is comparable to the USD$0.631 million reported for the prior year quarter. the year over year increase of USD$0.809 million was largely driven by the recent acquisition of Panoptes. Further contributing to the increased R&D costs were development costs for PP-001, as well as personnel related costs. EYEG stock’s increase in R&D expenses was partially offset by a decrease in costs related to OBG.

    G&A Costs and Net Income

    General and Administrative costs were reported at USD$1.306 million for the second quarter of fiscal 2021. This is comparable to the USD$1.09 million reported for the prior year quarter. The year over year increase of USD$0.216 million was largely attributable to increases in professional and personnel related costs. Other net income came in at USD$0.276 million for the second quarter of fiscal 2021, up significant from the USD$0.004 million reported for the prior year quarter. Q2 2021 saw EYEG stock report a gain of USD$0.278 million because of the full forgiveness of loan funds received under the Paycheck Protection Program.

    Solid Liquidity Position

    EYEG stock reported a solid liquidity position for the second quarter of fiscal 2021. As of June 30th 2021, the company had cash and cash equivalents in the amount of USD$3.663. This is a significant increase from the USD$1.186 million in cash and cash equivalents as of December 31st 2020. The year over year increase in cash and cash equivalents was largely driven by the completion of the company’s private placement in January of 2021. The year over year increase was partially offset by cash outflows that were allocated towards funding the company’s operations.

    Future Outlook for EYEG Stock

    EYEG stock reported a strong quarter, as evidenced by the strength of its financial reports for the second quarter of fiscal 2021. The company is poised to capitalize on the momentum generated over the course of the first half of fiscal 2021. Current and potential investors are hopeful that management will be able to facilitate a continued trajectory of success over the long term.

  • Immunome Inc. (IMNM) Stock Rises Following Success of IMM-BCP-01 in Treating Covid-19 Variants

    Immunome Inc. (IMNM) stock prices were up by 5.96% shortly after market trading commenced on September 7th 2021. This brought the price per share up to USD$16.00 early on in the trading day.

    IMM-BCP-01 Effective against Covid-19 Strains

    The biopharmaceutical company announced on September 7th 2021 that its three-antibody cocktail (IMM-BCP-01) exhibited potent neutralizing activity against the Lambda and Delta variants of Covid-19. The results came from pre-clinical testing conducted by the company on lentiviral-based pseudovirus. The treatment consists of three antibodies that bind to non-overlapping regions of the spike protein and exhibit synergistic activity against various strains of the global coronavirus.

    Scope of IMNM Stock’s Treatment

    IMM-BCP-01 is continuing to demonstrate its potential for the broad neutralization of various emerging Covid-19 variants in preclinical testing, the most recent of which were the highly concerning Lambda and Delta plus variants. The United States has been seeing an increasing number of cases of the Delta variant, making it the dominant straint, while the Lambda variant is proliferating South America as a variant of interest, as designated by the World Health Organization (WHO).

    Continued Trajectory of Success

    The treatment was designed to be resistant to variants of the coronavirus and preclinical data thus far has been highly encouraging. The results instill further confidence that the treatment could be essential in curbing and dealing with the persistent coronavirus pandemic. The treatment has already demonstrated an ability to neutralize all other current Centers for Disease Control (CDC) variants of concern during the pre-clinical testing phase. The project was funded by the United States Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical, in conjunction with the Defense Health Agency.

    About IMNM Stock

    The biopharmaceutical company leverages its human memory B cell platform to facilitate the discovery and development of first-in-class antibody therapeutics. Aiming to change the way diseases are treated, IMNM stock’s initial focus is on developing treatments to address oncology and infectious diseases, including Covid-19.

    Future Outlook for IMNM Stock

    The company reported a promising quarter, consolidated by the success of its flagship treatment in neutralizing emerging Covid-19 variants. IMNM stock is poised to capitalize on the opportunities afforded to it as the global pandemic continues to persist. Investors are hopeful that the company will be able to continue their trajectory of success over the long term.

  • Recon Technology Ltd. (RCON) Stock Surged Following Announcement of New Oil Sludge Disposal Contract

    Recon Technology Ltd. (RCON) stock prices were up by 0.050% shortly after market trading commenced on September 7th, 2021. This brought the price per share up to USD$3.21 early on in the trading day.

    RCON Stock’s Contract with PetroChina

    September 7th, 2021 saw RCON stock announce signing a service contract with PetroChina. This agreement is geared towards the hazardous waste disposal technology service project of a network of oil production plants in the Yumen Oilfield. The contract period has been set for one year and is valued at roughly USD$1.4 million. As per the contract, the company is required to transfer and ensure the safe disposal of almost 6000 tons of hazardous waste. Included in these services will be the removal of oily sludge temporarily stored in various oil production plants in Yumen Oilfield.

    RCON Stock’s Presence in Yumen City

    The company has secured a 50-year land use right for 26,235.59 square meters in Yumen City. A production line was constructed with an annual treatment capacity of 60,000 tons of oilfield oily waste comprehensive utilization. In conjunction with harmless comprehensive disposal (Oil Sludge Treatment Project), cumulative investment came out to a total of roughly USD$6.19 million. RCON stock has also reported achieving a necessary and scarce hazardous waste operating limit, which was issued by the Jiuquan Environmental Protection Bureau in Gansu Province.

    Expanding Contracts

    The company has reported being awarded six contracts for the disposal of sludge from facilities that produce oil under the Yumen Oilfield. Service tonnage of individual contracts went from tens of tons to hundreds of tons to thousands of tons per contract. RCON stock’s sludge treatment project line is the only existing treatment facility in the Gansu Province.

    Continued Trajectory of Success

    The company is leading the charge in developing domestic oil sludge treatment technology, facilitating the continued improvement of its production and treatment process. This is expected to result in increased awareness and recognition from oilfield companies, as well as the obtaining of new service contracts. Thus far, the company has signed an aggregate of roughly USD$2.8 million in service contracts.

    Future Outlook for RCON Stock

    The company reported a stellar quarter, consolidated by the awarding of various oil sludge disposal contracts. RCON stock is poised to capitalize on the opportunities afforded to the company as a result of its recent developments. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.

  • 111 Inc. (YI) Stock Surges Following Announcement of Share Repurchase Program

    111 Inc. (YI) Stock Surges Following Announcement of Share Repurchase Program

    111 Inc. (YI) stock prices closed the trading day on September 3rd, 2021 at USD$6.56, the same price it opened at. Subsequent current market fluctuations saw the stock surge by 5.95%, bringing it up to USD$6.95.

    YI Stock Invests in Growth

    The second quarter of fiscal 2021 saw YI stock continue investing in the development of its industry-leading technology. The company reported a 186% year-over-year increase in technology expenses, which accounted for 1.7% of net revenues for Q2 2021. This is comparable to the 1.1% of net revenues reported in the prior-year quarter. the company’s increased investments in technology yielded results, facilitating the obtaining of a total of 18 patients for its internally-developed proprietary technology in areas of digital health, big data analytics, and SMART supply chain technology.

    YI Stock’s 1 Clinic Solution

    The company’s cutting-edge technology solutions serve to support their internal efficient supply chain infrastructure. The solutions also enable customers to better serve their customers using the company’s SaaS enterprise solutions, which is particularly beneficial for pharmacies in YI stock’s network. Furthermore, the company has continued to cater to healthcare providers with more innovative solutions. This includes 1 Clinic, which offers e-hospital service and seamlessly connects patients with appropriate doctors through its digital solutions. This makes the platform very attractive for pharmaceutical companies that are seeking to launch and commercialize new drugs in China.

    Network of Partnerships

    YI stock has commenced various partnerships with several pharmaceutical companies that are seeking to leverage the company’s technology and network to commercialize their products. Partners include Eli Lily’s Trulicity, Taltz, and Verzenio, with a focus on treating diabetes, severe plaque psoriasis, and metastatic breast cancer. The company has also partnered with Novartis’ Consentyx for the treatment of plaque psoriasis, as well as Sanofi’s Dupixent, for the treatment of Eczema.

    Share Repurchase Program

    September 7th, 2021 saw YI stock announce a share repurchase program which authorizes the company to repurchase up to USD$10 million of its Class A ordinary shares. These purchases will be in the form of American Depositary Shares (ADS) over the course of the next 12 months.

    Future Outlook for YI Stock

    The company reported a promising end to the first half of fiscal 2021, as evidenced by the strength of its financial reports for Q2 2021. YI stock is poised to capitalize on the opportunities afforded to is as a result of its growing network of partnerships. Current and potential investors are hopeful that management will be able to facilitate significant and sustained increases in shareholder value over the long term.